Compare BCBP & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | INBX |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 999.7M |
| IPO Year | 2005 | 2024 |
| Metric | BCBP | INBX |
|---|---|---|
| Price | $8.21 | $62.24 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 71.0K | ★ 127.8K |
| Earning Date | 04-21-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $85.26 | $563.00 |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $7.31 | $10.81 |
| 52 Week High | $10.38 | $94.57 |
| Indicator | BCBP | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 31.92 |
| Support Level | $7.84 | $28.54 |
| Resistance Level | $8.66 | $85.97 |
| Average True Range (ATR) | 0.21 | 4.19 |
| MACD | -0.00 | -0.84 |
| Stochastic Oscillator | 62.50 | 14.09 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.